DexCom Investors Face Late-December Deadlines in Suits Over FDA-Flagged CGM Changes
Investor law firms set late-December deadlines tied to suits referencing an FDA warning over unauthorized CGM sensor changes.
Overview
- Notices from The Gross Law Firm, Kessler Topaz, Kirby McInerney, Rosen Law Firm, and Levi & Korsinsky set motions to be lead plaintiff due December 26 or December 29, 2025.
- Filings cite differing class periods, including January 8, 2024 to September 17, 2025; July 26, 2024 to September 17, 2025; and January 8, 2024 to July 25, 2024, which affects investor eligibility.
- Complaints allege DexCom made unauthorized design changes to its G6 and G7 sensors, overstated performance claims, and downplayed health risks tied to device inaccuracies.
- The FDA published a March 2025 Warning Letter stating the G6 and G7 were adulterated due to unapproved sensor modifications that increased inaccuracies for users making insulin dosing decisions.
- Investor notices reference share price drops following DexCom’s March SEC disclosure, the FDA letter’s publication, an Oppenheimer downgrade in September, and a Hunterbrook report alleging severe patient harms.